Sabiporide

Drug Profile

Sabiporide

Alternative Names: BIIB 722CL

Latest Information Update: 14 Nov 2014

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Anti-ischaemics; Guanidines; Small molecules
  • Mechanism of Action Sodium hydrogen antiporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ischaemic heart disorders

Most Recent Events

  • 28 Oct 2003 A preclinical study has been added to the Ischaemic Heart Disease pharmacodynamics section
  • 25 Nov 2002 Clinical trials in Ischaemic heart disorders in Germany (unspecified route)
  • 11 Sep 2001 Preclinical development for Reperfusion injury in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top